Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation

@inproceedings{sberg2013InclusionOC,
  title={Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation},
  author={Anders {\AA}sberg and Karsten Midtvedt and Mike van Guilder and Elisabet St\orset and Sara Bremer and Stein Bergan and Roger W. Jelliffe and Anders Hartmann and Michael Neely},
  booktitle={Transplant international : official journal of the European Society for Organ Transplantation},
  year={2013}
}
Following organ engraftment, initial dosing of tacrolimus is based on recipient weight and adjusted by measured C(0) concentrations. The bioavailability and elimination of tacrolimus are affected by the patients CYP3A5 genotype. Prospective data of the clinical advantage of knowing patient's CYP3A5 genotype prior to transplantation are lacking. A nonparametric population model was developed for tacrolimus in renal transplant recipients. Data from 99 patients were used for model development and… CONTINUE READING
9 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

25

  • Holford NH. Mechanistic basis of using body size Anderson BJ, maturation to predict clearance in humans. Drug Metab Pharmac 2009, 24
  • 1206 © 2013 The Authors Transplant International…
  • 2013
Highly Influential
5 Excerpts

836

  • Hebert MF Isoherranen N et al. Effect of CYP3A5 polymorph Dai Y, 34
  • © 2013 The Authors Transplant International…
  • 2013
1 Excerpt

the ‘ReSpECT’ study

  • JM Neuberger, RD Mamelok, P Neuhaus, tacrolimus et al. Delayed introduction of reduced-dose, transplantation renal function in liver
  • Am J Transplant 2009; 9: 327. © 2013 The Authors…
  • 2013

Similar Papers

Loading similar papers…